Updated:
Juvenescence
Juvenescence operates as a biotech platform that advances medicines targeting the fundamental biology of aging. Co-founded by Dr.
Juvenescence
Juvenescence operates as a biotech platform that advances medicines targeting the fundamental biology of aging. Co-founded by Dr. Greg Bailey — who led the $26 billion in acquisitions behind Pfizer-Medivation and Pfizer-Biohaven — the firm assembles drug programs around mechanisms that drive multiple age-related conditions. Its approach spans modalities from small-molecule compounds to cell therapies, backed by a leadership group with over 150 years of combined R&D experience and a record of multiple drug approvals. The pipeline shows an early-intervention thesis gaining clinical traction. A Phase 1 trial of a PAI-1 inhibitor completed in early 2026, and the firm aims to have five programs in human testing by 2025. Confirmed collaborators include the Buck Institute’s Eric Verdin, whose lab presented data on a Juvenescence compound in December 2025. Geographically, Juvenescence has expanded into the Middle East, strengthening its UAE presence in Masdar City’s Life Science Innovation Cluster in February 2026 while maintaining a public presence at investment forums in London and Singapore. The organization runs lean on available headcount figures but draws on a veteran drug-development network. February 2026 marked the appointment of Eileen Jennings-Brown as Chief Technology Officer alongside the firm’s reinforced UAE footprint. Its scientific leadership also includes Gill Dines as Chief Scientific Officer, who presented data at the ARDD conference in September 2025. While Juvenescence does not disclose a dedicated philanthropic vehicle, its core mission — extending healthy lifespan — inherently aligns with public-health goals, and prior investor communications reference delivering 200x returns to backers. What separates Juvenescence structurally from conventional biotech and longevity-focused family offices is its origins in a dealmaking machine. Instead of originating from a single tech fortune or an academic spinout, the firm was built by principals with a track record of massive pharma M&A and product approvals. That transactional DNA shapes a model where platform-company creation and secondary exits sit alongside clinical advancement, positioning Juvenescence as an investment-engine-and-biotech hybrid rather than a pure-play drug developer.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
British Virgin Islands
City
New York
Corporate office
New York, British Virgin Islands
Principals
Greg Bailey
Co-Founder
Eileen Jennings-Brown
Chief Technology Officer
Sector focus
Frequently asked questions
What is Juvenescence’s core therapeutic strategy?
Juvenescence develops medicines that target core aging mechanisms to prevent age-related disease. Their programs span small molecules, biologics, and cell therapies, with a stated commitment to having five medicines in Phase I or II trials by 2025. The focus is on early disease intervention rather than late-stage treatment, leveraging mechanisms such as PAI-1 inhibition that recently completed a Phase 1 trial.
Who leads the scientific and drug-development decisions?
Co-Founder Dr. Greg Bailey drives strategy, drawing on his experience leading the $26 billion in acquisitions behind Pfizer-Medivation and Pfizer-Biohaven. The R&D leadership includes Gill Dines as Chief Scientific Officer and newly appointed CTO Eileen Jennings-Brown, supported by a team the firm says has over 150 years of combined pharma experience and multiple prior drug approvals.
How does Juvenescence relate to other biotech platforms or family offices in longevity?
Juvenescence is not a single-family office or a university spinout; it operates as an investment-driven biotech platform. Its founders come from pharma dealmaking and product approvals, not a single liquidity event, which gives the firm a hybrid structure: it builds and advances clinical assets while pursuing secondary exits that have returned 200x to investors on certain past transactions.
What geographies does Juvenescence operate in?
Juvenescence lists a registered address in New York and the British Virgin Islands. It maintains an active scientific and investor presence in the UK and recently strengthened its UAE operations by joining Masdar City’s Life Science Innovation Cluster in February 2026. The team has presented at conferences in London, Singapore, and the UAE.
Are there any philanthropic or foundation structures alongside Juvenescence?
Juvenescence does not publicly disclose a separate philanthropic vehicle. Its core mission — extending healthy lifespan through preventive medicine — is framed as a public-health contribution in its own right, but there is no named foundation or charitable entity directly linked to the firm in available materials.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: